The National Institutes of Health’s Rapid Acceleration of Diagnostics (RADx®) Tech program is working to identify necessary elements of at-home COVID-19 diagnostic test kits that may be used independently by people with disabilities.
The NIH RADx initiative today announced the launch of the When To Test Calculator for Individuals, a companion to the version for organizations introduced last winter. By responding to just a few prompts, the new individual impact calculator indicates whether a person should get a test—now or soon.
NIH is investing about $74.5 million over five years to advance data science, catalyze innovation and spur health discoveries across Africa. Under its new Harnessing Data Science for Health Discovery and Innovation in Africa (DS-I Africa) program.
NIH is investing $70 million from the American Rescue Plan to help bring more high-quality, at-home tests onto the market in the U.S. in coordination with the FDA. NIH’s new Independent Test Assessment Program (ITAP) will establish an accelerated pathway to support FDA evaluation of tests with potential for large-scale manufacturing.
The NIH RADx initiative announced today that it has issued contract awards totaling $77.7 million to develop and manufacture 12 new rapid diagnostic tests for SARS-CoV-2, the virus that causes COVID-19. The home and point-of-care testing platforms target the need for high-performance, low-cost home tests and point-of-care tests that can potentially detect multiple respiratory infections.
NIBIB selected three winning teams for designs that excel according to four criteria: the significance of the problem being addressed; the impact on clinical care; the innovation of the design; and the ideation process or existence of a working prototype.
In a study that compares rapid antigen and laboratory PCR approaches for COVID-19 serial screening, researchers affiliated with the NIH RADx initiative reported results from 43 people infected with the virus.